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Objectives. The purpose of this study was to determine whether 
intravenous dextrose albumin sonicated with a commonly used 
gas of low blood solubility and diffusivity (periluoropropane) 
could identify acute myocardial ischemia nd reperfusion. 
Background. Recently, it has been demonstrated that dextrose 
albumin sonicated with gases that have low blood solubility and 
diffusivity results in microbubbles capable of consistently produc- 
ing myocardial ultrasound contrast after intravenous injection. It 
remains to be determined, however, whether this contrast agent 
can visually detect he myocardial blood flow abnormalities seen 
with acute ischemia or stunned myocardium after reperfusion. 
Methods. We gave intravenous injections (0.06 ml/kg body 
weight) of perfluoropropane-exposed sonicated extrose albumin 
to 10 open chest dogs. The measured degree of myocardial 
contrast (0+ to 2+) and background-subtracted p ak anterior 
myocardial videointensity produced from each injection were 
measured at three stages: 1) under baseline conditions, 2) during 
acute ischemia produced by a proximal eft anterior descending 
coronary artery ligation lasting 10 to 120 rain, and 3) after reflow 
was established. Coronary blood flow was monitored uring all 
injections by using an ultrasound flow probe placed around the 
left anterior descending artery. 
Results. Coronary blood flow ranged from 0 to 137 ml/min, and 
peak myocardial videointensity after intravenous administration 
of perfluoropropane-exposed sonicated extrose albumin ranged 
from 0 to 70 gray scale U. There was consistent visual myocardial 
opacification i  all dogs during baseline conditions and a visually 
evident decrease in myocardial contrast in the left anterior 
descending artery distribution after ligation. A relative increase in 
contrast in this same distribution after intravenous contrast agent 
administration occurred in 7 of the 10 dogs during reflow. 
Quantitatively, there was an excellent correlation in individual 
dogs between peak myocardial videointensity and coronary flow at 
all stages (mean correlation coefficient 0.95 -+ 0.04, range 0.87 to 
0.99). 
Conclusions. Perfluoropropane-exposed sonicated extrose al- 
bumin is an ultrasound contrast agent hat can visually identify 
myocardial perfusion abnormalities from a peripheral venous 
injection. 
(J Am Coll Cardiol 1995;26:33-40) 
Identification of abnormal myocardial blood flow with the use 
of myocardial contrast echocardiography as usually required 
that the contrast injections be given as intracoronary or aortic 
root injections (1-4). Although this approach is useful in the 
cardiac catheterization laboratory, contrast echocardiography 
has not been able to noninvasively identify abnormalities in 
myocardial blood flow in humans because intravenously in- 
jected microbubbles do not persist long enough to produce 
myocardial contrast. 
One method of overcoming this problem has been to inject 
high concentrations of sonicated albumin into the right atrium. 
This approach as produced consistent myocardial opacifica- 
tion if the contrast agent is given during pharmacologic 
hyperemia (5,6). More recently, ultrasound contrast agents 
have been formulated that are capable of producing myocar- 
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dial contrast from a peripheral intravenous injection (7-9). 
One method of achieving myocardial contrast from an intra- 
venous injection is to prolong microbubble survival by incor- 
porating a gas of low blood solubility and diffusivity into the 
microbubbles. One such gas is perfluoropropane, which is 
commonly used in intraocular surgery for tamponade of the 
retina (10,11). Mixing a gas such as this with dextrose albumin 
microbubbles has been shown to produce consistent myocar- 
dial opacification after intravenous injection (12). However, 
the ability of this type of microbubble contrast o identify and 
quantify myocardial ischemia is unknown. In this study we 
tested the ability of dextrose albumin sonicated with perflu- 
oropropane to identify both ischemic and reperfused myocar- 
dium after intravenous injection. 
Methods  
The study involved 10 mongrel dogs. Each dog underwent 
intravenous edation with sodium pentobarbital and subse- 
quent endotracbeal intubation and ventilation with room air. 
An open thoracotomy was performed, and the heart suspended 
in an epicardial cradle. A warm water bath was placed over the 
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anterior surface of the heart, and a 3.5-MHz imaging trans- 
ducer (Hewlett-Packard) was adjusted to produce ashort-axis 
view of the left ventricle at the midpapillary muscle level. A silk 
or umbilical tape ligature was placed around the left anterior 
descending coronary artery and tightened uring the study to 
produce total occlusion of the vessel. The entire study was 
approved by the Animal Care and Use Committee at the 
University of Nebraska Medical Center and was in compliance 
with the Position of the American Heart Association on 
Research Animal Use. 
We placed 7F sheaths in both the right and the left femoral 
artery and vein. Hemodynamic monitoring throughout each 
study was performed with a 7F Swan-Ganz catheter and 7F 
pigtail catheter placed in the pulmonary artery and left ventri- 
cle, respectively. Cardiac output was obtained by a thermodi- 
lution technique before and after injections of ultrasound 
contrast medium. 
A 2.0-mm transit ime ultrasound flow cuff (Transonic, Inc.) 
was placed around the proximal left anterior descending 
coronary artery to continuously monitor coronary blood flow. 
Therefore, for each injection of contrast medium, both cardiac 
output and left anterior descending artery blood flow were 
monitored. 
Preparation of perfluoropropane-exposed sonieated dex- 
trose albumin. We obtained 5% human serum albumin and 
5% dextrose in water from the University of Nebraska Medical 
Center pharmacy. Three parts 5% dextrose and one part 5% 
human serum albumin (total 16 ml) were drawn into a 35-ml 
Monoject syringe. The Leur-Lok of the 35-ml syringe was then 
attached to a three-way stopcock that was also attached to a 
syringe containing 5 ml of perfluoropropane gas (Fig. 1). The 
gas was obtained from a tank containing perfluoropropane 
(purity 99.0%; <10 ppm total hydrocarbons; molecular weight 
184 g/mole [Air Products and Chemicals, Inc.]) by using sterile 
tubing and a nonpyrogenic filter (Cammeo IIS, Micron Sepa- 
rations Inc.). 
After the dextrose albumin solution was mixed by hand for 
7 to 10 s, the plunger was removed from the top of the syringe. 
The sterile sonicating horn was then lowered into the open end 
of the syringe until it reached the surface of the albumin- 
dextrose solution. The solution was placed at the horn tip and 
manually held at this position while continuous sonication at a 
frequency of 20 kHz proceeded for 80 2 5 s. 
The sonicating system, made by Heat Systems Inc., has a 
sonicating horn with a theoretic maximal energy output of 
550 W. According to the manufacturer, the transference of this 
electrical energy to mechanical energy is -90% (495 W). 
Energy output was manually adjusted by using the digital scale 
to achieve 25 _+ 3% of this maximal output during the entire 
sonication time (124 _+ 15 W). Because this energy is emitted 
vertically from the circular 0.5 in. (1.27-cm) horn tip, the 
output from the horn tip is estimated to be 98 2 11 W/cm 2 for 
the 80-s time period. 
During sonication, the 5 ml of perfluoropropane in the 
12-ml syringe was slowly introduced into the dextrose albumin 
by means of the stopcock (Fig. 1), a method of gas delivery 
J 
PF 
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Figure 1. Illustration of the methods used to expose the dextrose 
albumin to perfluoropropane gas(PF) during sonication. During the 
sonication procedure, 5 ml of perfluoropropane is infused through the 
dextrose albumin solution. SDA = sonicated dextrose albumin. 
similar to that described by Reisner et al. (13,14). After 
sonication, the microbubble solution was placed in a vertical 
position in a 35-ml syringe until a distinct upper white layer 
(5 ml) and a lower clear layer (20 ml) formed. The lower clear 
layer was decanted, whereas the upper white layer was used for 
intravenous injections. 
The mean size of microbubbles prepared by using this 
technique was determined by measurement of six consecutive 
samples of perfluoropropane-exposed sonicated extrose albu- 
min. As assessed with hemocytometry, the mean size of these 
six samples was 4.7 +_ 0.3 ~m. Microbubble concentration was 
measured with a Coulter counter. Because the concentration 
of microbubbles xceeded the measurement capabilities of the 
Coulter counter when we attempted to measure the concen- 
trated upper white layer, we calculated the concentration f
this layer by first measuring the concentration f microbubbles 
in the entire 25-ml sample with the Coulter counter. As the 
average of this concentration was 1.2 _+ 0.2 x 109 micro- 
bubbles/ml, we calculated that the concentration of micro- 
bubbles in the concentrated upper layer was five times this 
value or 6.0 × 109/ml. 
Study protocol. The standard dose of intravenous 
perfluoropropane-exposed sonicated extrose albumin for all 
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Figure 2. Examples ofthe visual grading of myocar- 
dial contrast enhancement (arrows) in the myocar- 
dium after an intravenous injection of perfluoropro- 
pane-exposed sonicated dextrose albumin. A, 0+ = 
no contrast; 1+ = mild contrast enhancement. B, 
2+ - marked contrast enhancement. 
injections at baseline and during ischemia nd reperfusion was 
0.06 ml/kg body weight. This dose, shown in previous tudies 
(12) to produce consistent myocardial opacification without 
significant hemodynamic effects, was given in the femoral vein 
and followed by a 10-ml saline flush administered over 4 to 6 s. 
Intravenous injections of this dose of perfluoropropane- 
exposed sonicated extrose albumin were first given during 
baseline conditions. A silk or umbilical tape ligature placed 
around the proximal eft anterior descending coronary artery 
was then tightened to produce zero blood flow with the flow 
cuff, and the same intravenous injections were repeated. 
Myocardial images obtained after each injection of intravenous 
perfluoropropane-exposed onicated dextrose albumin were 
recorded on videotape for off-line analysis (see later). The 
duration of ischemia varied; if the dog began exhibiting 
significant ventricular arrhythmias, this time period was kept 
short but was never <10 min. If the dog was in bemodynam- 
ically stable condition, the duration of ligation continued up to 
120 min. This variable time period was also used to simulate 
the clinical counterpart in humans, in whom the duration of 
vessel occlusion before reperfusion may also va U from minutes 
to hours. 
After the period of ischemia, the ligation was removed and 
the degree of hyperemic blood flow measured with the flow 
probe was recorded. Injections of intravenous perfluoropropane- 
exposed sonicated extrose albumin were then repeated. To 
determine whether the anterior myocardial contrast videoin- 
tensity produced with intravenous perfluoropropane-exposed 
sonicated extrose albumin could detect different coronary 
flow rates (including hyperemic flow), the first intravenous 
injection of the contrast agent was given within 5 min of release 
of the occlusion. A range of two to four injections/dog were 
given after reperfusion over a period of 30 min. All coronary 
blood flow measurements were made immediately before the 
contrast injections because of attenuation of the ultrasound 
flow signal during the injections. 
Analysis of contrast enhancement, Myocardial videointen- 
sity from the mid-anteroseptal portion of the myocardium was 
measured off-line from high fidelity videotape images (Maxell 
SVHS, Japan). Transmit power and time gain compensation 
settings on the ultrasound system (Hewlett-Packard Sonos 
1500, model 77035A) were kept constant for all dogs at all 
stages in the study. Gray scale software (Freeland Prism 
Review Station) that quantitates videointensity (on a scale 
from 0 to 255) versus time was used to measure peak video- 
intensity from a region of interest in the anteroseptal myocar- 
dium at end-systole for 30 consecutive cycles beginning just 
before contrast appearance in the left ventricular cavity. 
A region of interest was chosen (ranging from 25 to 160 
pixels) that obtained videointensity from the anteroseptal 
myocardium but avoided endocardial nd epicardial borders. 
This region had to be reduced during the period of acute 
ischemia in some dogs because of myocardial thinning. Peak 
videointensity was determined by averaging the pixel intensity 
in the region of interest over three cardiac cycles at the peak 
portion of the time-intensity curve. To correct for background 
videointensity, the average videointensity in the myocardium 
immediately before contrast appearance was subtracted from 
this value. No curve smoothing of the time-intensity curve was 
performed. The region of interest was kept in a constant 
position by manually aligning the region of interest within the 
myocardium for every cardiac cycle. Injections of intravenous 
perfluoropropane-exposed onicated extrose albumin were 
repeated two to three times during baseline conditions to 
perform measurements of reproducibility. 
Visually evident myocardial contrast in the anteroseptal 
myocardium was qualitatively assessed after these same intra- 
venous injections by using a grading system of 0+ = no 
myocardial contrast, 1+ = mild contrast enhancement i  the 
myocardium and 2+ = marked contrast enhancement in 
the myocardium (Fig. 2). One experienced cardiologist visually 
interpreted all 65 intravenous injections of perfluoropropane- 
exposed sonicated extrose albumin for the degree of myocar- 
dial contrast. From these interpretations, a correlation coetfi- 
cient was calculated between the visual degree of myocardial 
contrast and coronary flow. In 28 randomly selected cases, a 
second cardiologist independently interpreted the degree of 
contrast in the myocardium on the same 0+ to 2+ scale in 
order to test interobserver variability. Each person was blinded 
to the other eviewer's interpretation as well as to the stage of 
the study in which the injections were given. 
No quantitative measurements of contrast-derived area at 
risk could be made at peak myocardial videointensity because 
of attenuation f the inferoseptal border of the contrast defect 
as a result of left ventricular cavity contrast. 
Regional left ventricular wall thickening in the left anterior 
descending artery perfusion bed was measured at each 
setting by using videotape analysis of the end-diastolic and 
36 PORTER ET AL. JACC Vol. 26, No. 1 
ULTRASOUND CONTRAST TO DETECT ABNORMAL PERFUSION July 1995:33-40 
Table 1. Changes in Hemodynamic and Flow Variables After Intravenous Injection of 
Perfluoropropane-Exposed Sonicated Dextrose Albumin (0.06 ml/kg) at Baseline and During Acute 
Myocardial Ischemia nd Reperfusion in 10 Dogs (mean _+ SD) 
Baseline Ischemia Reperfusion 
BC AC BC AC BC AC 
LVSP (mm Hg) 98 + 12 100 + 12 93 + 18 95 -+ 20 95 -+ 24 90 -+ 36 
LVEDP (mm Hg) 3 * 2 4 -+ 4 6 -+ 2* 6 + 2 6 + 3* 5 -+ 2 
MPA(mm Hg) 20 = 5 23 ± 6 21 _+ 4 23 _+ 6 24 +_ 5 26 +_ 6 
CO (liters/min) 3.1 : 1.0 3.3 = 1.3 2.1 _+ 0.6* 2.3 _+ 0.8 2.1 +_ 1.0' 2.2 _+ .07 
*p < 0.05 versus baseline (analysis of variance). AC after ultrasound contrast injection; BC = before ultrasound 
contrast injection; CO = cardiac output: LVKDP left ventricular end-diastolic pressure; LVSP = left ventricular 
systolic pressure; MPA - mean pulmona~, artery pressure. 
end-systolic frames (defined as the largest and smallest left 
ventricular chamber sizes in the cardiac cycle, respectively). 
The average wall thickness from the midportion of the antero- 
septal segment in the short-axis view was determined by 
calculating the difference in end-diastolic and end-systolic wall 
thickness, and dividing this number by end-diastolic wall 
thickness (expressed as a percent). 
Determination of myocardial infarction. After the last 
ultrasound contrast injection, the dog was killed. To 
document whether infarction occurred, the heart was sliced 
and immersed in a solution containing 1.3% 2,3,5- 
triphenyltetrazolium chloride and 0.2 tool/liter Tris buffer at 
37°C for 20 min. With this technique, any infarcted areas 
should not stain, whereas noninfarcted areas should stain brick 
red (15). 
Statistical analysis. Peak myocardial videointensity from 
the anteroseptal region and coronary flow in the left anterior 
descending artery from repeated intravenous injections of 
contrast agent at all three stages (baseline, acute ischemia, 
reperfusion) in individual dogs were compared by using a 
Pearson correlation coetficient. This same coetficient was used 
to compare the correlation between cardiac output and peak 
myocardial videointensity after contrast agent injection as well 
as the correlation between the visual degree of myocardial 
contrast enhancement and corona~" blood flow. Paired t 
testing was used to compare changes in hemodynamic mea- 
surements before and after intravenous perfluoropropane- 
exposed sonicated extrose albumin at all three stages. Anal- 
ysis of variance was utilized to compare differences in 
hemodynamic data, cardiac output and wall thickening during 
the three stages. 
(peak myocardial videointensities, coronary flows and wall 
thickening measurements) during baseline and during acute 
ischemia in these two dogs are included in the pooled analysis. 
In all three stages of the study, the intravenous contrast 
injections did not significantly alter left ventricular end- 
systolic, end-diastolic or mean pulmonary artery pressures. 
However, left ventricular end-diastolic pressure was signifi- 
cantly higher than baseline values before the injections during 
the ischemia and reperfusion stages. Cardiac output also did 
not change after any injection of ultrasound contrast medium, 
but was significantly lower than baseline values before contrast 
injections during acute ischemia nd reperfusion. 
Peak myocardial videointensity produced with intravenous 
contrast injections (Table 2). Table 2 demonstrates left ante- 
rior descending artery flow, anteroseptal wall thickening, and 
peak anteroseptal myocardial videointensity after intravenous 
injections of perfluoropropane-exposed sonicated extrose al- 
bumin during the three stages of the study. Anteroseptal wall 
thickening decreased significantly during acute ischemia. Al- 
though there was a slight improvement in wall thickening 
during the reperfusion stage, average wall thickening remained 
akinetic or dyskinetic in five dogs and hypokinetic n three (two 
dogs died before this stage was reached). 
The 10 dogs received a total of 65 intravenous 
perfluoropropane-exposed sonicated extrose albumin injec- 
tions (range 4 to 9 injections/dog). Figure 3 is an example of 
the time-intensity curves produced in the left ventricular cavity 
and anterior myocardium after one intravenous injection. Peak 
myocardial videointensity could not be accurately quantified 
after two injections in one dog during the ischemic stage 
because the region of interest could not consistently be kept 
Resu l ts  
Hemodynamic effects of intravenous contrast injections 
(Table 1). Table 1 demonstrates hemodynamic and cardiac 
output changes before and after intravenous injections of 
perfluoropropane-exposed sonicated extrose albumin during 
the three stages of the study (baseline, ischemia nd reperfu- 
sion). All 10 dogs had intravenous contrast injections per- 
formed at baseline and during acute ischemia, but 2 dogs died 
before the reperfusion stage could be performed. The data 
Table 2. Changes (mean _+ SD) in Left Anterior Descending 
Coronary. Artery. Flow, Wall Thickening and Peak Videointensity at
Baseline and During Acute Myocardial Ischemia nd Reperfusion 
Baseline Ischemia Repeffusion 
LAD flow (ml/min) 36 = 27 0* 59 -+ 35* 
PVI 24 = 11 5 _+ 7* 40_+ 18 
WT (~'~) 40 _- 8 -10 +_ 10" 2 _+ 10' 
*p < 0.05 versus baseline (analysis of variance). LAD = left anterior 
descending coronary artery.; PVI - peak videointensity; WT= wall thickening. 
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Figure 3. Example of time-intensity curve in the Left ventricular (LV) 
cavity and anteroseptal myocardium after intravenous injection of 
perfluoropropane-exposed s nicated dextrose albumin. 
between epicardial and endocardial reflectors owing to myo- 
cardial thinning. Therefore, no correlation between peak myo- 
cardial videointensity and left anterior descending artery flow 
could be measured in this dog. The range of coronary blood 
flows observed immediately before the injections in the 10 dogs 
was 0 (during ligation of the left anterior descending artery) to 
137 ml/min (immediately after eperfusion). Peak background- 
subtracted videointensities after intravenous contrast injection 
during all three stages from the anteroseptal myocardium 
ranged from 0 to 70 gray scale U. The correlation coefficient 
between peak myocardial videointensity and left anterior de- 
scending artery flow changes in individual dogs was excellent 
(mean r value 0.95 _+ 0.04, range 0.87 to 0.99). Figure 4 is an 
example of the strong correlation between changes in left 
anterior descending artery flow and peak myocardial video- 
intensity in two dogs. The relation between coronary blood 
flow and peak myocardial videointensity in all dogs combined 
was not as good (r = 0.87, p < 0.001, SE 2.9 ml). There was 
only a weak correlation between peak videointensity from the 
anteroseptal myocardium and cardiac output (r = 0.28, p = 
O.O6). 
Of the 65 intravenous injections in the 10 dogs, 24 were 
given during baseline, 22 during acute ischemia nd 19 during 
reperfusion. At baseline, visually graded myocardial contrast 
enhancement i  he anteroseptal myocardium was judged to be 
1+ after 18 injections and 2+ after 6 injections. During 
ischemia, there was no evidence of contrast enhancement 
(grade 0+) after 21 of the 22 injections, and 1+ after one 
injection. In this stage, a visually evident contrast defect could 
also be visualized (Fig. 5) that appeared smaller than the 
extent of wall thickening abnormality. However, this contrast 
defect could not be measured by planimetry at peak myocar- 
dial intensity, because the inferoseptal border of the defect was 
not visualized ue to attenuation of the image by left ventric- 
ular cavity contrast (Fig. 5). During reperfusion, 14 of the 19 
injections resulted in 2+ contrast enhancement i  the antero- 
septal myocardium, and 4 injections produced 1+ contrast 
enhancement. After one injection during reperfusion, no con- 
trast enhancement was produced. This corresponded to a 
period in which left anterior descending artery flow had 
decreased to 11 ml/min after a brief hyperemic period of 
89 ml/min immediately after removal of the ligation. This dog 
had only a brief duration of occlusion (10 rain), but it was 
complicated by ventricular fibrillation and persistent severe 
hypokinesia in the anteroseptal myocardium after reflow. 
Figure 6 demonstrates the close correlation between the visual 
assessment of myocardial contrast produced by intravenous 
perfluoropropane-exposed onicated extrose albumin and 
coronary blood flow in all three stages of the study. 
Twenty-eight of the intravenous injections were judged by 
two independent experienced reviewers to determine interob- 
server variability on the visual assessment of contrast grade. 
The reviewers agreed on 24 (86%) of the 28 injections and 
disagreed by one grade on 4. 
Results of staining. The postmortem 2,3,5-triphenyltetrazo- 
lium chloride staining demonstrated no infarction within the 
Figure 4. Graph demonstrating 
the correlation between left ante- 
rior descending coronary artery 
(LAD) blood flow and peak 
myocardial videointensity pro- 
duced by 0.06-ml/kg intravenous 
injections of perfluoropropane- 
exposed sonicated dextrose albu- 
min in two dogs. Videointensity - 
peak anteroseptal myocardial 
videointensity. 
Dog 1 
60 ~ y=0.571X÷193 
r=0.99 
50 ! n=8P<0"O001 
40 
_-2 i 
~z 30 i 
g 20j 
10 
I 
0 
, /  
I T -  I ] "~ 
20 40 60 80 100 
LAD Flow ( ml/min ) 
100 
80 
60 
40 
20 
Dog 2 
y=0.508X+7,17 
r=-O95 
p<0.001 
n=8 
J 
/ J  j J  
J 
I i i I 7 - -  , i 
0 20 40 60 80 100 120 140 160 
LAD Flow ( ml/min ) 
38 PORTER ET AI~. : JACC VoL 26, No. 1 
ULTRASOUND CONTRAST TO DETECT ABNORMAl.  PERFUSION July 1995:33-40 
Figure 5. Myocardial images obtained at 
baseline before intravenous injection of 
perfluoropropane-exposed s nicated dextrose 
albumin (A), showing baseline contrast video- 
intensity after the injection (B) and contrast 
videointensity during acute anteroseptal isch- 
emia (C) and after reperfusion of the left 
anterior descending coronary artery (D). Af- 
ter the injection during iscbemia (C), there is 
a visually evident decrease in myocardial con- 
trast in the anteroseptal myocardium (white 
arrows) from the baseline contrast level (B). 
During reperfusion (D), a visually evident 
increase in myocardial opacification (black 
arrows) after the same intravenous dose of 
contrast medium corresponded to coronary 
hyperemia. 
region of interest in 8 of the 10 dogs: subendocardial nfarction 
was evident within the region of interest in 2 dogs. There were no 
differences inthe visual myocardial contrast produced by intrave- 
nous perfluoropropane-exposed sonicated extrose albumin dur- 
Figure 6. Graph demonstrating the corrclation between the visual 
assessment ofanterior myocardial contrast produced by an intravenous 
injection of perfluoropropane-exposed sonicated extrose albumin and 
coronary flow. 0+, l -  and 2+ as defined in Figure 2. 
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ing the reperfusion stage in the dogs with or without subendocar- 
dial infarction. 
Reproducibility of peak intensity measurements. Because 
of the variability in coronary flow, the coefficient of variation 
for repeated measurements of peak myocardial videointensity 
after two sequential intravenous injections of perfluoropro- 
pane-exposed sonicated dextrose albumin could be made 
during baseline conditions in only 6 of the 10 dogs. The mean 
value for the peak anterior myocardial videointensity produced 
by the first intravenous injection of perfluoropropane-exposed 
sonicated extrose albumin was 26 _+ 12 gray scale U, com- 
pared with 24 + 11 for the second injection of the same dose 
under constant baseline conditions. The correlation coefficient 
comparing the two repeated measurements was 0.89 (p < 
0.01). The mean coefficient of variation for repeated measure- 
ments of peak myocardial videointensity when coronary flow 
was constant was 16 _+ 10%. 
Discuss ion 
In this study, we demonstrated that an ultrasound contrast 
agent formulated by sonicating dextrose albumin with a gas of 
low solubility and diffusivity (perfluoropropane) could visually 
identify acutely ischemic and reperfused myocardium after a 
peripheral intravenous injection. In addition, the peak myo- 
cardial videointensity measured off-line with this intravenous 
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contrast agent correlated closely with relative changes in 
coronary blood flow in each dog. We also observed no signif- 
icant changes in left ventricular pressure, pulmonary artery 
pressure or cardiac output after intravenous injection of this 
agent during any stage of the study, indicating that intravenous 
perfluoropropane-exposed sonicated extrose albumin is capa- 
ble of safely and consistently producing myocardial contrast 
from an intravenous injection. This agent, therefore, has the 
potential to noninvasively identify myocardial ischemia, and 
determine whether eperfusion has occurred in the treatment 
of acute myocardial infarction. 
Noninvasive detection of acute myocardial ischemia. 
There was a visually evident reduction in myocardial contrast 
in the anteroseptal myocardium in all 10 dogs after ligation of 
the left anterior descending coronary artery. This reduction 
was accompanied by either akinesia or dyskinesia in the 
anteroseptal myocardium. Although area at risk measurements 
have been made with left main artery injections of ultrasound 
contrast medium (16,17), a quantitative measurement of area 
at risk could not be obtained with intravenous perftuoropropane- 
exposed sonicated extrose albumin because the inferior border 
of the area at risk could not be visualized at peak myocardial 
videointensity as a result of left ventricular cavity contrast 
attenuation. In addition, the anterior border of the area at risk 
is not as clear with intravenous injections because the degree of 
contrast achieved in the adjacent normal zone is lower than 
that seen with a left main artery injection (Fig. 5). Nonetheless, 
the decrease in contrast in the anteroseptal myocardium 
during left anterior descending artery occlusion provided clear 
evidence of an ischemic zone that visually did not appear to 
extend as far as the wall thickening abnormality. 
Noninvasive identification of reperfused myocardium. Left 
anterior descending artery reperfusion resulted in coronary 
blood flows that exceeded baseline flow in seven dogs. Intra- 
venous injections of perfluoropropane-exposed sonicated ex- 
trose albumin in this setting resulted in a visually evident 
increase over baseline values in myocardial contrast in the 
perfusion bed of the left anterior descending artery (Fig. 5). 
This increase in contrast intensity was not accompanied by 
normalization of wall thickening. All 10 dogs bad residual 
hypokinesia, kinesia or dyskinesia, although postmortem data 
revealed no evidence of infarction in the region of interest in 
8 dogs and evidence of only subendocardial infarction in 2. 
Intravenous perfluoropropane-exposed sonicated extrose al- 
bumin, therefore, was able to demonstrate whether eperfu- 
sion occurred while wall thickening abnormalities remained 
nearly the same as during ischemia. 
These findings demonstrate he potential value of intrave- 
nous perfluoropropane-exposed sonicated extrose albumin in 
the early management of patients with acute myocardial 
infarction. In this study intravenous injections of this agent 
rapidly identified whether coronary patency had been 
achieved. This agent, therefore, could be utilized to noninva- 
sively determine whether coronary artery patency is achieved 
in patients with acute myocardial infarction treated with 
intravenous treptokinase or tissue-type plasminogen activa- 
tor. Documentation of reperfusion is critical in this setting, 
because arlier patency of the infarct-related vessel has been 
associated with improved survival (18). Intravenous perfluoro- 
propane-exposed sonicated dextrose albumin could rapidly 
identify whether such patency has been established and thus 
facilitate decision making in the early stages of acute myocar- 
dial infarction. 
Limitations of the study. In this study we used peak 
myocardial videointensity as one means of determining coro- 
nary blood flow. This variable of the time-intensity curve may 
be limited in quantifying coronary flow because 1) it has a 
nonlinear elation with coronary flow changes at higher video- 
intensities, and 2) peak myocardial videointensity correlates 
more closely with myocardial blood volume changes than with 
flow changes (19,20). With regard to the relation between flow 
and myocardial videointensity, the range of peak myocardial 
videointensities produced in the myocardium was in the lower 
range of the 0 to 255 gray scale (0 to 70 gray scale U). Because 
the relation between flow and peak videointensity becomes 
nonlinear at higher videointensities owing to instrument satu- 
ration, we assume that our close correlation with flow in the 
individual dogs occurred because our videointensities were in 
the lower, more linear range. Second, it has been observed (21) 
that peak myocardial videointensity produced with ultrasound 
contrast is a function of both myocardial blood flow and 
volume. We could not directly measure tissue blood volume 
changes in this study, but the close relation we observed 
between coronary blood flow and peak myocardial videointen- 
sity changes within dogs suggests that the flow changes we 
induced were closely coupled to the myocardial blood volume 
changes. Using a left anterior descending artery stenosis 
model, Skyba et al. (21) also demonstrated a close relation 
between myocardial blood volume and flow changes. 
Although we could easily identify anteroseptal myocardial 
perfusion with intravenous perfluoropropane-exposed soni- 
cated dextrose albumin in all cases, the posterior wall was not 
visualized because of left ventricular cavity contrast attenua- 
tion (Fig. 5). This also prevented the direct measurement of
area at risk after intravenous injection of the agent during 
acute ischemia. To identify posterior ischemia, different echo- 
cardiographic views (such as the apical long-axis view) that 
prevent he posterior wall from being attenuated by the cavity 
may be necessary. In addition, decreasing the dose of ultra- 
sound contrast should decrease the amount of cavity shadow- 
ing. However, this decrease will require further improvement 
of the persistence of microbubble size after intravenous injec- 
tion, so that the lower dose of microbubbles injected can 
produce the same degree of videointensity. 
Finally, rest injections of intravenous perfluoropropane- 
exposed sonicated extrose albumin after reperfusion were not 
able to differentiate the dogs with subendocardial infarction 
from those with no necrosis. Villanueva et al. (6) demonstrated 
that contrast enhancement from right atrial injections of 
sonicated albumin detect infarction only when they are given 
during pharmacologic hyperemia with dipyridamole. We did 
not give adenosine or dipyridamole in our dogs after repeffu- 
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sion which may explain why we did not detect he subendocar- 
dial areas of infarction in the two dogs that demonstrated this 
with triphenyltetrazolium staining. 
Conclusions. Intravenous perfluoropropane-exposed oni- 
cated dextrose albumin can consistently and safely identify 
acutely ischemic and reperfused myocardium. The magnitude 
of contrast intensity correlates closely with relative coronary, 
blood flow changes in these settings. This ultrasound contrast 
agent, therefore, could be useful in rapidly and noninvasively 
assessing coronary, blood flow' changes in the infarct-related 
artery during the treatment of acute myocardial infarction in 
humans. 
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